Browse studies

Find your next paid study

13 recruiting studies matching your filters

Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies

Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers…

Hematologic Neoplasms

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05327023

Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers…

Hematologic MalignanciesHematologic Neoplasms

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07162038

Phase 1

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-ve…

Hematologic Neoplasms

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04959175

Phase 2

Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies

Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person…

Core Binding Factor Alpha SubunitsHematologic NeoplasmsLeukemia+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07524530

Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members

This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specime…

NeoplasmsHematologic NeoplasmsHealthy Volunteers

Estimated

~$10 – $675

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT00071045

Phase 1

A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended ph…

Hematologic Neoplasms

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Janssen Research & Development, LLCNCT07572006

The Rutgers University Study of the Genetics of Blood Cancers

The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online…

Blood CancersBlood CancerLeukemia+6 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Rutgers, The State University of New JerseyNCT07714044

Phase 1

A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN)

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this i…

Systemic Mastocytosis With an Associated Hematologic Neoplasm

Estimated

~$150 – $3,000

Actual pay is set by the research site.

H. Lee Moffitt Cancer Center and Research InstituteNCT06327685

Phase 2

A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patien…

Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Cogent Biosciences, Inc.NCT04996875

Observational

Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation

A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HC…

Cognitive ImpairmentHematologic NeoplasmsHematopoietic Cell Transplant

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Alabama at BirminghamNCT03094026

Observational

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NG…

Myeloid MalignancyInherited Bone Marrow Failure SyndromeClonal Expansion+10 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT02958462

Phase 1

A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatmen…

Hematologic Neoplasms

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Kyowa Kirin Co., Ltd.NCT07629726